© 2024 Kansas City Public Radio
NPR in Kansas City
Donate
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Up To Date

Coronavirus Vaccine Trials Are Making Progress — But There's Still A Long Way To Go

By Steve Kraske,
Mackenzie Martin
Published November 16, 2020 at 4:02 PM CST
Ways To Subscribe
Barbara Pahud talks outside Truman Medical Center-Lakewood on Thursday about the AstraZeneca COVID vaccine trial.
Carlos Moreno
/
KCUR 89.3
Dr. Barbara Pahud from Children's Mercy Hospital talks outside Truman Medical Center-Lakewood on November 12 about the AstraZeneca COVID-19 vaccine trials in Kansas City.

Even as pharmaceutical companies announce high success rates in their most recent trials, life won't return to normal anytime soon.

Dr. Barbara Pahud — part of the team leading the AstraZeneca vaccine trials in Kansas City — says more research needs to be done and that everyone should be prepared to socially distance and wear masks through 2021.

More information about the ongoing clinical COVID-19 vaccine trials can be found at CoronavirusPreventionNetwork.org.

Tags
Up To Date Talk ShowKansas City Missouri (KCMO)Coronavirusvaccinesmedical researchChildren's Mercy HospitalUniversity of Kansas Medical CenterPodcastHealth
Stay Connected
Steve Kraske
When I host Up To Date each morning at 9, my aim is to engage the community in conversations about the Kansas City area’s challenges, hopes and opportunities. I try to ask the questions that listeners want answered about the day’s most pressing issues and provide a place for residents to engage directly with newsmakers. Reach me at steve@kcur.org or on Twitter @stevekraske.
See stories by Steve Kraske
Mackenzie Martin
Mackenzie Martin is a senior podcast producer at KCUR Studios and host of the podcast, A People's History of Kansas City. Contact her at mackenzie@kcur.org.
See stories by Mackenzie Martin
Support paywall-free journalism
KCUR prides ourselves on bringing local journalism to the public without a paywall — ever.

Our reporting will always be free for you to read. But it's not free to produce.

As a nonprofit, we rely on your donations to keep operating and trying new things. If you value our work, consider becoming a member.
Donate Now